|
Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators |
Dec 2024 |
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria |
Dec 2024 |
Expert Review of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Real-World Study of the Burden of Myelodysplastic Syndromes in Patients and Their Caregivers in Europe and the United States |
Dec 2024 |
Oncology and Therapy |
Myelodysplastic Syndromes (MDS) |
|
Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes |
Dec 2024 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
RNA splicing as a therapeutic target in myelodysplastic syndromes |
Dec 2024 |
Seminars in Hematology |
Myelodysplastic Syndromes (MDS) |
|
Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape |
Dec 2024 |
Immunotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
Nov 2024 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
|
Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial |
Nov 2024 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists |
Nov 2024 |
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Health-related quality of life and symptom-specific functional impairment among patients treated with parenterally administered complement inhibitors for paroxysmal nocturnal hemoglobinuria |
Nov 2024 |
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
